<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81659">
  <stage>Registered</stage>
  <submitdate>19/10/2006</submitdate>
  <approvaldate>2/11/2006</approvaldate>
  <actrnumber>ACTRN12606000460505</actrnumber>
  <trial_identification>
    <studytitle>Prenatal diagnosis of Down's Syndrome using isolation of foetal cells from cervical mucous and peripheral blood during first trimester of pregnancy</studytitle>
    <scientifictitle>Prenatal diagnosis of Down's Syndrome using isolation of foetal cells from cervical mucous and peripheral blood during first trimester of pregnancy in women</scientifictitle>
    <utrn />
    <trialacronym>NPD</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Pregnant women</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Down's syndrome</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single peripheral blood sample obtained by venupuncture at 10-12 weeks gestation, immediately prior to CVS. A single cervical mucous sample obtained by aspiration catheter at 10-12 weeks gestation, immediately prior to CVS.                                                                                                                                                                                                                                 The whole period of the study is 24 months.</interventions>
    <comparator>A control group undergoing prenatal testing (Chorionic Villous Sampling at 10-12 weeks) but not participating in blood or cervical mucous sampling.</comparator>
    <control>Active</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sensitivity of the assay to detect Down Syndrome is assessed within 24 hours after the samples have been obtained.</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Miscarriage Rate</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pregnant women presenting for Chorionic Villous Sampling. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnant women not requiring an invasive test.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Genetic scientists (assessors) and Data Analyst will be blinded for comparison of study results and routine karyotyping</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/02/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>2000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genetic Technologies Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Genetic Technologies Ltd</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Genetic Technologies Ltd</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The trial is to investigate novel non-invasive methods for the prenatal diagnosis of Down Syndrome by isolation of foetal cells from peripheral blood and cervical mucous.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Debbie Mantzaris</name>
      <address>Genetic Technologies Ltd
60-66 Hanover Street
Fitzroy VIC 3065</address>
      <phone>+61 3 84127012</phone>
      <fax>+61 3 94176863</fax>
      <email>Debbie.Mantzaris@gtg.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Richard Allman</name>
      <address>Genetic Technologies Ltd
60-66 Hanover Street
Fitzroy VIC 3065</address>
      <phone>+61 3 84127005</phone>
      <fax>+61 3 94176863</fax>
      <email>Richard.Allman@gtg.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>